Attached files

file filename
EX-31.2 - EX-31.2 - KalVista Pharmaceuticals, Inc.kalv-ex312_297.htm
EX-31.1 - EX-31.1 - KalVista Pharmaceuticals, Inc.kalv-ex311_296.htm
10-Q - 10-Q - KalVista Pharmaceuticals, Inc.kalv-10q_20170731.htm

 

 

Exhibit 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the accompanying Quarterly Report of KalVista Pharmaceuticals Inc. (the Company) on Form 10-Q for the fiscal quarter ended July 31, 2017 (the Report), I, T. Andrew Crockett, as Chief Executive Officer of the Company, and Benjamin L. Palleiko, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: September 14, 2017

 

/s/ T. Andrew Crockett

 

 

T. Andrew Crockett

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

Dated: September 14, 2017

 

/s/ Benjamin L. Palleiko

 

 

Benjamin L. Palleiko

Chief Financial Officer

(Principal Financial and Accounting Officer)